Abstract: A peptide capable of binding to Lanthionine synthetase C-like (LanCL) protein, wherein the peptide comprises an amino acid sequence of formula (I): X1-X2-X3-X4-X5-X6??(I) wherein: (a) X1 is selected from the group consisting of lysine, arginine and histidine, or X1 is absent; (b) X2 is selected from the group consisting of alanine, valine, leucine, isoleucine, proline, phenylalanine, cysteine, tyrosine and serine; (c) X3 is selected from the group consisting of glycine, alanine, valine, leucine and isoleucine; (d) X4 is selected from the group consisting of serine, cysteine, threonine, asparagine, arginine, glutamine, tyrosine, aspartic acid, lysine, glutamic acid, proline and histidine, or X4 is absent; (e) X5 is selected from the group consisting of serine, cysteine, threonine, asparagine, arginine, glutamine, tyrosine, lysine, histidine and glycine, or X5 is absent; and (f) X6 is selected from the group consisting of serine, cysteine, threonine, asparagine, glutamine, tyrosine, and histidine, or X6 is

Abstract: The present disclosure relates generally to a method of screening for and identifying a ligand of a Lanthionine synthetase C-like protein (LANCL) and the use of the identified ligands for the treatment of conditions, including pain. Also disclosed herein is a method of treating a condition, including pain, comprising administering to a subject in need thereof a therapeutically effective amount of an agent that binds to Lanthionine synthetase C-like protein 1 (LANCL1), wherein the agent is not a peptide derived from human growth hormone, or from a non-human homologue thereof, and wherein the agent competes for binding to LANCL1 with a cyclic peptide comprising SEQ ID NO:1 (YLRIVQCRSVEGSCGF).

Abstract: The present disclosure is directed to a peptide of formula (I), or a pharmaceutically acceptable salt thereof, and uses thereof: R1—C—R—X1—X2—P—X3—X4—X5—X6—C—R2 (I) wherein X1, X3, X5, and X6 is an amino acid residue selected from the group consisting of serine, alanine, valine, leucine, isoleucine and glycine; X2 is alanine, arginine or lysine; X4 is glutamic acid or aspartic acid; R1 is selected from the group consisting of S, HS, GHS, PGHS, APGHS, EAPGHS, SEAPGHS, SSEAPGHS, PSSEAPGHS, DPSSEAPGHS and IDPSSEAPGHS, or R1 is absent; and R2 is selected from the group consisting of S, SS, SSK, SSKF, SSKFS, SSKFSW, SSKFSWD, SSKFSWDE, SSKFSWDEY, SSKFSWDEYE, SSKFSWDEYEQ, SSKFSWDEYEQY, SSKFSWDEYEQYK, SSKFSWDEYEQYKK, SSKFSWDEYEQYKKE, or R2 is absent; and wherein the peptide of formula (I), or the pharmaceutically acceptable salt thereof, is a cyclic peptide formed by a disulphide bond between the two cysteine residues.

Abstract: Disclosed herein are methods and compositions for treating or preventing neuropathic pain in a subject, the method comprising administering to a subject a therapeutically effective amount of prolactin, or a functional variant thereof, wherein the functional variant comprises a peptide of formula (I) or a pharmaceutically acceptable salt thereof: R1-C-R-I-X1-X2-X3-X4-N-C-R2 (I) (SEQ ID NO:1) wherein X1 is an amino acid residue selected from isoleucine (I) and valine (V); X2 is an amino acid residue selected from histidine (H) and tyrosine (Y); X3 is an amino acid residue selected from aspartic acid (D) and asparagine (N); X4 is an amino acid Nresidue selected from asparagine (N) and serine (S); R1 is selected from the group consisting of YLKLLK, LKLLK, KLLK, LLK, LL, K or R1 is absent; and R2 is G (glycine), or R2 is absent.

Abstract: The present disclosure relates to the use of C-terminal fragments of human and non-human growth hormone, synthetic cyclic peptides and C-terminal fragments of human prolactin precursor for the treatment of migraine in a subject in need thereof.

Abstract: A method of treating neuropathic pain in a subject, the method comprising administering to a subject a therapeutically effective amount of a peptide of formula (I) or (II), or a pharmaceutically acceptable salt thereof: R1-CRSVEG-SCG-R2 (I) (SEQ ID NO:1) wherein R1 is selected from the group consisting of YL-RIVQ, LRIVQ, RIVQ, IVQ, VQ, and Q, or R is absent; and R2 is F (phenylalanine) or R2 is absent. R1-CRRFVESSC-R2 (II) (SEQ ID NO:6) wherein R1 is selected from the group consisting of YLRVMIK, LRVMK, RVMK, VMK, MK, and K, or R1 is absent; and R2 is selected from the group consisting of A (alanie) and AF (alanine-phenylalanie), or R2 is absent.